Entrada Therapeutics (TRDA) director receives grant of 19,000 stock options

Rhea-AI Filing Summary

Entrada Therapeutics director Peter S. Kim received a grant of stock options covering 19,000 shares of common stock. The options have an exercise price of $5.97 per share and expire on June 10, 2036. According to the terms, they vest and become exercisable on the earlier of the one-year anniversary of June 10, 2026 or the company’s next annual meeting of stockholders.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider KIM PETER S

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	19,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 19,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Stock options granted: 19,000 options Underlying shares: 19,000 shares Exercise price: $5.97 per share +2 more

5 metrics

Stock options granted 19,000 options Grant to director Peter S. Kim on June 10, 2026

Underlying shares 19,000 shares Common stock linked to granted options

Exercise price $5.97 per share Price to purchase common stock upon exercise

Expiration date June 10, 2036 Option term end date

Post-transaction options held 19,000 options Total derivative position following grant

Key Terms

Stock Option (Right to Buy), exercise price, vest and become exercisable, annual meeting of stockholders

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "5.9700""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest and become exercisable financial

"The shares subject to this option shall vest and become exercisable"

annual meeting of stockholders financial

"the Issuer's next annual meeting of stockholders"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KIM PETER S

(Last) (First) (Middle)

C/O ENTRADA THERAPEUTICS, INC.

ONE DESIGN CENTER PLACE, SUITE 17-500

(Street)

BOSTON MASSACHUSETTS 02210

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Entrada Therapeutics, Inc. [ TRDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$5.97	06/10/2026		A		19,000		(1)	06/10/2036	Common Stock	19,000	$0	19,000	D

Explanation of Responses:

1. The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 10, 2026 or (ii) the Issuer's next annual meeting of stockholders.

Remarks:

	/s/ Jared Cohen, as Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Entrada Therapeutics (TRDA) report for Peter S. Kim?

Entrada Therapeutics reported that director Peter S. Kim received a grant of stock options for 19,000 shares of common stock. These options are a form of equity compensation, giving him the right to buy shares at a fixed exercise price in the future.

What is the exercise price of Peter S. Kim’s new Entrada Therapeutics (TRDA) stock options?

The granted stock options have an exercise price of $5.97 per share. This means Kim can purchase Entrada Therapeutics common stock at $5.97 once the options vest and become exercisable, regardless of the market price at that time.

When do Peter S. Kim’s Entrada Therapeutics (TRDA) stock options vest?

The options vest and become exercisable on the earlier of the one-year anniversary of June 10, 2026 or Entrada Therapeutics’ next annual meeting of stockholders. This schedule ties vesting to both a time-based milestone and a key corporate governance event.

How many Entrada Therapeutics (TRDA) options does Peter S. Kim hold after this grant?

After this transaction, Peter S. Kim holds 19,000 stock options according to the filing. These options each relate to one share of common stock, giving him a potential future right to acquire 19,000 shares if he exercises them.

Is Peter S. Kim’s Entrada Therapeutics (TRDA) option grant a market purchase or sale?

The transaction is a grant of stock options, not a market purchase or sale of shares. It is classified as an acquisition of a derivative security as compensation, with no open-market buying or selling reflected in this specific Form 4 entry.